Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-331574
Filing Date
2026-08-04
Accepted
2026-08-04 07:51:57
Documents
55
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pvla-20260630.htm   iXBRL 10-Q 2051529
2 EX-10.2 pvla-ex10_2.htm EX-10.2 60756
3 EX-31.1 pvla-ex31_1.htm EX-31.1 19224
4 EX-31.2 pvla-ex31_2.htm EX-31.2 19263
5 EX-32.1 pvla-ex32_1.htm EX-32.1 11694
6 EX-32.2 pvla-ex32_2.htm EX-32.2 11118
  Complete submission text file 0001193125-26-331574.txt   7687421

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pvla-20260630.xsd EX-101.SCH 928345
59 EXTRACTED XBRL INSTANCE DOCUMENT pvla-20260630_htm.xml XML 1378043
Mailing Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087
Business Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Filer) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37471 | Film No.: 261235537
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)